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ABSTRACT: Biopolymeric hydrogels have been widely used as carriers of therapeutic cells and drugs for biomedical
applications. However, most conventional hydrogels cannot be injected after gelation and do not support the infiltration of cells
because of the static nature of their network structure. Here, we develop unique cell-infiltratable and injectable (Ci-I) gelatin
hydrogels, which are physically cross-linked by weak and highly dynamic host−guest complexations and are further reinforced
by limited chemical cross-linking for enhanced stability, and then demonstrate the outstanding properties of these Ci-I gelatin
hydrogels. The highly dynamic network of Ci-I hydrogels allows injection of prefabricated hydrogels with encapsulated cells and
drugs, thereby simplifying administration during surgery. Furthermore, the reversible nature of the weak host−guest cross-links
enables infiltration and migration of external cells into Ci-I gelatin hydrogels, thereby promoting the participation of
endogenous cells in the healing process. Our findings show that Ci-I hydrogels can mediate sustained delivery of small
hydrophobic molecular drugs (e.g., icaritin) to boost differentiation of stem cells while avoiding the adverse effects (e.g., in
treatment of bone necrosis) associated with high drug dosage. The injection of Ci-I hydrogels encapsulating mesenchymal stem
cells (MSCs) and drug (icaritin) efficiently prevented the decrease in bone mineral density (BMD) and promoted in situ bone
regeneration in an animal model of steroid-associated osteonecrosis (SAON) of the hip by creating the microenvironment
favoring the osteogenic differentiation of MSCs, including the recruited endogenous cells. We believe that this is the first
demonstration on applying injectable hydrogels as effective carriers of therapeutic cargo for treating dysfunctions in deep and
enclosed anatomical sites via a minimally invasive procedure.
■ INTRODUCTION
Various natural and synthetic materials have been used as
potential carrier biomaterials of cell or therapeutic agents for
tissue regeneration.1−6 Hydrogels with highly hydrated
polymeric networks are ideal carriers for encapsulating cells
and drugs.7−12 However, most conventional hydrogels that
allow cells encapsulation are based on static chemical cross-
linking and lack dynamic properties such as self-healing and
injectability.13−15 These limitations preclude the delivery of
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cargo agents by the hydrogel carriers to anatomically deep and
enclosed defects via minimally invasive procedures, which have
become increasingly popular because of demands for aesthetic
appearance and expeditious postsurgery recovery.16 Further-
more, the rigid and nondegradable nature of chemically cross-
linked hydrogels hinders the recruitment and infiltration of host
cells into implanted hydrogels, thereby limiting the extent of in
situ regeneration and integration of implanted biomaterials into
host tissues.17,18
Many previous studies have demonstrated the fabrication of
dynamic hydrogels stabilized by reversible physical cross-linking
including hydrogen bonds, hydrophobic interactions, ionic
interactions, ligand−ion coordination, dipole−dipole interac-
tions, and host−guest complexations.19−37 These physically
cross-linked hydrogels exhibit many desirable properties
including self-healing and injectability.38−44 However, because
of the weak nature of physical cross-linking and the stringent
demands of cell-friendly preparation, few studies have reported
physical hydrogels that are sufficiently cytocompatible and
stable to allow for encapsulation and long-term culture of cells
and to provide continued support to the encapsulated cells in
vivo after delivery.
In this study, we develop unique cell-infiltratable and
injectable (Ci-I) gelatin hydrogels, which are stabilized largely
by the physical cross-linking of host−guest complexation and
are further reinforced by limited chemical cross-linking (Scheme
1), and then demonstrate the outstanding properties of these Ci-
I gelatin hydrogels. Our Ci-I gelatin hydrogels can be preformed
with encapsulated therapeutic cells and drugs first, maintained
under culture conditions for a desired period, and injected to
target sites in the gel form at a prescribed time because of their
excellent injectability and remoldability. Furthermore, the
reversible physical cross-links of the Ci-I hydrogels also support
infiltration of cells into the hydrogels that are loaded with
chemoattractant drugs. These unique capabilities of Ci-I
hydrogels offer great convenience during surgical procedures
and significantly expedite clinical operations. We further
evaluated the efficacy of the Ci-I gelation hydrogels as carriers
of therapeutic drugs and cells for treating an enclosed bone
abnormality in steroid-associated osteonecrosis (SAON) of the
femoral head.
Steroids are widely used for treating various clinical
conditions, such as rheumatoid arthritis, organ transplantation,
and respiratory syndrome.45−49 However, long-term steroid
treatments may lead to SAON, commonly affecting large joints
such as the hip.50−52 A surgical core decompression (CD)
procedure is typically performed on patients with early stage
SAON to remove the necrotic bone and implant bone substitute
in the drilled tunnel to prevent subsequent decreases in bone
mineral density and support bone regeneration.53,54 Since the
lack of endogenous stem cells and aberrant accumulation of
adipose tissues were recognized as main characteristics of SAON
in previous studies,55,56 here, we evaluated the feasibility of the
Ci-I gelatin hydrogels encapsulating mesenchymal stem cells
(MSCs) and a hydrophobic small molecule, icaritin, as a bone
substitute to treat rat SAON (Scheme 1). Our in vivo animal
research showed that the MSCs and icaritin-laden Ci-I gelatin
hydrogels can prevent a decrease in bone mineral density
(BMD) and promote in situ bone regeneration. Moreover, the
icaritin-laden hydrogels enhanced the recruitment and infiltra-
tion of cells from the surrounding host tissues to the
implantation sites, further confirming the efficacy of our Ci-I
Scheme 1. Preparation of the Cell-Infiltratable and Injectable (Ci-I) Gelatin Hydrogels and the Treatment of SAON with Ci-I
Hydrogels as the Carrier of Therapeutic Cargoes (Cells and Drug) in the Rat Model
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hydrogels for promoting in situ regeneration. To the best of our
knowledge, this is the first study demonstrating the feasibility of
using injectable hydrogels encapsulating stem cells and small
molecules to treat bone disorders in deep and enclosed
anatomical locations, e.g., SAON at the hip.
■ RESULTS AND DISCUSSION
Prefabricated Ci-I Hydrogels Adapt to Injection Site
Geometry and Maintain Initial Mechanical Properties
after Injection. Gelatin has been extensively used for various
biomedical applications because of its biocompatibility,
bioactivity, biodegradability, and availability.57,58 Gelatin hydro-
gels are especially useful as carrier materials of therapeutic cells
and drugs.59−61 However, the preparation of conventional
chemically cross-linked gelatin hydrogels entails chemical
modifications of the gelatin, and the obtained hydrogels are
brittle with restricted network dynamics.62−64 Therefore, in this
study, we developed a strategy to prepare gelatin hydrogels
containing both chemical and physical cross-linking based on
unmodified gelatin. First, the synthesized free diffusing photo-
cross-linkable Ac-β-CDs (acryloyl β-cyclodextrin, 1.5 acryloyl
groups per Ac-β-CDmolecule on average, i.e., a fraction of Ac-β-
CDs bear more than one acryloyl group, Figure S1) were
coupled to the aromatic residues of gelatin (e.g., phenylalanine,
tyrosine, and tryptophan) via host−guest interactions. Sub-
sequently, UV-initiated polymerization of the Ac-β-CDs led to
Figure 1. (a) Ci-I gelatin hydrogels displayed a frequency-dependent response in the rheological frequency sweep test at a strain of 0.1% and 37 °C. (b)
Ci-I hydrogels exhibited a sol−gel transition during switching between alternating high (1000%, unshaded region) and low (1%, shaded region) shear
strain in the rheological test at 37 °C. (c) A preformed Ci-I gelatin hydrogel was drawn into a syringe and then injected through a G21 needle into a
culture plate well (used as the mold) to be remolded to the shape of the cell culture well. (d) Ci-I gelatin hydrogels sustained over 95% of compressive
strain without rupture before or after injection. (e) Stress vs strain curves from a cyclic compression test of Ci-I hydrogels (peak strain, 60%; loading
speed, 1 mm/s) at 37 °C (inset: plot in the strain range 50−60%).
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the formation of gelatin hydrogels containing two types of cross-
links: (1) the physical host−guest complexations between the
aromatic residues of the gelatin and oligomerized Ac-β-CDs,
which are distributed throughout the entire hydrogel network;
and (2) the chemical cross-links (due to the fraction of Ac-β-
CDs bearing more than one acryloyl group) among the
oligomerized Ac-β-CDs, the distribution of which is sparse
and localized because of the inefficient reaction among the bulky
Ac-β-CDs. The following experiments demonstrated that these
gelatin hydrogels not only possessed unique dynamic properties
including self-healing, shear-thinning, injectability, and cell
infiltration capability due to the physical host−guest cross-
linking but also showed adequate stability because of the
localized chemical cross-linking for supporting long-term 3D
culture of encapsulated cells. These hydrogels are therefore
referred to as the “cell-infiltratable and injectable gelatin
hydrogels” (Ci-I gelatin hydrogels) in the following sections.
The rheological measurements further demonstrated the
presence of both physical and chemical cross-linking within the
Ci-I gelatin hydrogels. The Ci-I hydrogels showed an obvious
frequency-dependent increase in the modulus (Figure 1a),
indicating the involvement of the physical host−guest complex-
ation between gelatinous aromatic groups and β-CDs in
stabilizing the hydrogel network. The further rheological studies
revealed a “sol−gel” transition of the Ci-I hydrogels under
alternating high/low shear strain (Scheme 1). The Ci-I
hydrogels switched to the “sol” state (G″ > G′) under a high
shear strain of ∼1000% and immediately recovered to the “gel”
state (G′ > G″) under a subsequent low shear strain of 1%
(Figure 1b). Moreover, even after repeated high/low shear
loading cycles, the storage modulus (G′) of the Ci-I hydrogels
consistently recovered to ∼80% (1050 Pa) of that of the freshly
prepared unloaded samples (1373 Pa) (Figure 1b). This slight
reduction in storage modulus is likely attributed to the partial
disruption of chemical cross-linking under loading. This
excellent shear-thinning and self-healing capability enables the
injection of Ci-I hydrogels without significantly compromising
their mechanical properties. The prefabricated Ci-I hydrogel
disks injected through a G21 needle into cylindrical models were
efficiently remolded to regain the original disk morphology
(Figure 1c). Moreover, the compression test showed that the
injection did not significantly affect the mechanical properties of
the Ci-I gelatin hydrogels, and the injected hydrogels could still
sustain over 95% compressive strain without rupture as could
the noninjected hydrogels (Figure 1d). Furthermore, after the
first loading−unloading cycle, the Ci-I hydrogels exhibited
almost coinciding loading−unloading stress versus strain curves
obtained from the remaining loading cycles (peak strain: 60%),
suggesting excellent resistance to excessive cyclic compression
(Figure 1e). Previous studies65−68 proved that well-designed
injectable hydrogels could prevent encapsulated cells from
damage of shear force during the injection through the syringe
needle. To study whether our Ci-I gelatin hydrogels could
maintain the viability of the encapsulated cell during the
injection, we cultured hMSC-ladenCi-I gelatin hydrogels in vitro
for 1 day before injecting the hydrogels through a G21 needle,
and the injected hydrogels were further cultured in vitro for
another 5 days. Figure S3 shows that the cell viability is still
>90% even after injection, demonstrating the effective
protection of the encapsulated cells by the injectable Ci-I
gelatin hydrogels.
Ci-I Hydrogels Mediate Sustained Delivery of a
Hydrophobic Chemoattractant and Support Infiltration
of Cells. Sustained delivery of small hydrophobic molecules via
hydrogels is typically challenging because the hydrophilic nature
and large mesh size of hydrogel networks make loading and
long-term release of small hydrophobic molecules rather
difficult. Because a significant excess of Ac-β-CDs (compared
with gelatinous aromatic residues) were used to fabricate Ci-I
hydrogels, there were a considerable number of unoccupied β-
Figure 2. (a) Kinetics of small-molecule icaritin release from the Ci-I gelatin hydrogels at 37 °C. The confocal micrographs show the 3D distribution of
DAPI-stained human mesenchymal stem cell (hMSC) nuclei within the Ci-I hydrogels without (b) or with (c) icaritin encapsulation after 24 h of in
vitro culture. (d) Schematic illustration of a cell migration experiment at 37 °C. hMSCs seeded on the surface of the icaritin-ladenCi-I gelatin hydrogels
infiltrated into the hydrogels within 24 h. (e) Invasion distance of DAPI-stained hMSC nuclei clusters within the Ci-I gelatin hydrogels without icaritin
and Ci-I gelatin hydrogels with icaritin. The thickness of the Ci-I hydrogels used for the cell migration test is 1 mm, and the scanning depth of the Ci-I
hydrogels is 500 μm in the cell migration experiments. Scale bar: 100 μm (parts b and c).
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CD moieties conjugated to the hydrogel network. β-CD is
commonly used in the pharmaceutical industry to improve the
solubility of hydrophobic drugs.69−71 We utilized the empty β-
CD cavities in Ci-I hydrogels to deliver a small hydrophobic
chemical molecule, icaritin, which can reduce SAON incidence
by inhibiting both thrombosis and lipid deposition.72 The
icaritin-laden Ci-I gelatin hydrogels were capable of releasing
icaritin continuously for up to 2 weeks (Figure 2a). Therefore,
these findings demonstrate that the injectable Ci-I gelation
hydrogels can serve as a promising delivery vehicle of small
hydrophobic molecular drugs for treating pathological con-
ditions including SAON in a minimally invasive fashion.
Our previous research also showed that an anabolic and
potent molecule icaritin can function as a chemoattractant to
induce the directed migration of MSCs within a short time
frame.72 The dynamic and weak cross-links based on host−guest
complexation of our Ci-I gelatin hydrogel can potentially
support cell infiltration and migration. To demonstrate this, we
seeded MSCs on the surface of Ci-I hydrogels with or without
the loaded icaritin. After 24 h of culture, most MSCs still
remained on top of the hydrogels without icaritin (Figure 2b,e
andMovie S1), whereas nearly all MSCs infiltrated andmigrated
into the hydrogels loaded with icaritin (Figure 2c−e and Movie
S2). The degradation of the hydrogels by cell-secreted catabolic
Figure 3. (a) Cell viability staining (green corresponds to live cells, and red corresponds to dead cells) ofMSC-ladenCi-I gelatin hydrogels after 1 week
and 2 weeks of culture. (b) Gene expression of selected osteogenic markers (alkaline phosphatase (ALP) and Runx2) and adipogenic markers (CEBPα
and PPARγ) of MSCs encapsulated in Ci-I gelatin hydrogels after 7 and 14 days of culture. Each sample was internally normalized to GAPDH, and
every group was compared to the expression levels of group 100Dex on day 7, the quantitative value of which was set to unity. The data were analyzed
with two-way ANOVAwith Tukey’s post hoc test (n = 4, *P < 0.05, **P < 0.01, ***P < 0.001, compared to the 500Dex group). (c) Von Kossa staining;
(d) immunohistochemical staining of Runx2, OCN, CEBPα, and PPARγ of the hMSCs loaded in Ci-I gelatin hydrogels after 7 and 14 days of culture.
100Dex, 100 nM dexamethasone (Dex) in media; 500Dex, 500 nM Dex in media; 500Dex+icaritin (M), 500 nM Dex and 1 mM icaritin in media;
500Dex+icaritin (H), 500 nMDex in media and 1.3 mM icaritin in the hydrogel. The total amount of icaritin in the 500Dex+icaritin (M) group is the
same as that in the 500Dex+icaritin (H) group. Scale bar: 100 μm (parts a, c, and d).
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enzymes might not be significant enough to support such
extensive cell infiltration within the short period of 24 h. We
speculated that the cell infiltration was likely facilitated by the
disruption of the weak host−guest cross-links in Ci-I hydrogels
by cellular forces. Therefore, we speculate that, once implanted
into the defect sites, the icaritin-laden Ci-I gelatin hydrogels can
promote the recruitment and infiltration of endogenous cells
into the hydrogel matrix, thereby speeding up the repair and
regeneration of bone defects.
Ci-I Hydrogel Attenuates the Adverse Effect of High-
Dosage Corticosteroid during Stem Cell Differentiation.
We then evaluated the efficacy of the Ci-I hydrogel as an
injectable carrier of therapeutic cells to treat SAON by
examining the osteogenesis of MSCs encapsulated in the Ci-I
gelatin hydrogels in the presence of a high concentration of
Figure 4. (a) Micro-CT images and HE staining of the native bone around the tunnel and the new bone inside the tunnel after 3 and 6 weeks
postinjection of Ci-I hydrogels in SAON rats. Quantitative analysis of micro-CT for the bone in the “peri-tunnel” (b) and “within tunnel” (c) space.
One-way ANOVA with Tukey’s post hoc tests were used to analyze the data (n = 6, *P < 0.05, **P < 0.01, ***P < 0.001). (d) Goldener’s Trichrome
staining of the bonelike tissue within the bone tunnel. Scale bar: 500 μm (micro-CT images in part a); 100 μm (HE staining in part a and Goldener’s
staining in part d).
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corticosteroid. The majority of MSCs encapsulated in the Ci-I
gelatin hydrogels were viable and spread to adopt a stellate
morphology after 2 weeks of culture (Figure 3a), indicating that
the dynamic Ci-I hydrogel network provides a permissive 3D
environment to facilitate cell−matrix interactions. Then, we
evaluated the differentiation of MSCs encapsulated in hydrogels
under different culture conditions. Previous studies showed that
dexamethasone (Dex), a clinically used corticosteroid, improved
the osteogenesis of MSCs at low concentration but promoted
the adipogenesis of MSCs at high concentration.73,74 Our RT-
PCR data indeed showed that a low media concentration of Dex
(100 nM, “100Dex”) promoted the expression of osteogenic
markers (ALP and Runx2), whereas a high media concentration
(500 nM, “500Dex”) of Dex up-regulated the expression of
adipogenic markers of the MSCs encapsulated in hydrogels
(CEBPα and PPARγ) (Figure 3b). In contrast, media
supplementation of icaritin effectively suppressed the expression
of adipogenic marker genes and promoted that of osteogenic
marker gene, alkaline phosphatase (ALP), of the encapsulated
MSCs under a high media concentration of Dex (Figure 3b,
Figure 5. (a) Quantitative analysis of cells positive for Ki67 (Figure S4 for corresponding images) and (b) cells positive for both Osterix and Runx2
using immunofluorescent staining. The data were analyzed with one-way ANOVA with Tukey’s post hoc test (n = 4). (c) Immunofluorescent staining
at week 6 after SAON surgical treatment in SD rats (negative control group in Figure S5). RepresentativeWestern Blot images from three independent
experiments for osteogenic markers (osteocalcin and active β-catenin) (d), and adipogenic markers (CEBPα and PPARγ), proliferative marker
(PCNA), inflammatory marker (tyrosine-kinase transmembrane receptor for CSF1), and indicator for osteonecrosis (c-Src) (e) (n = 3 per condition;
Lane 1, blank repair; Lane 2, Gel; Lane 3, icaritin+Gel; Lane 4, icaritin+MSC+Gel). Injection of Ci-I gelatin hydrogels, which were loaded with both
MSCs and icaritin (“icaritin+MSC+Gel”), activated β-catenin and osteocalcin signaling but inhibited the inflammatory response and adipogenesis.
The quantitative data are shown in Figure S6. (f) Sequential labeling of newly formed bone with calcein green (CG) and xylenol orange (XO) in the
methyl methacrylate-embedded icaritin+MSC+Gel sample at week 3 postsurgery. OB, old bone; T, bone tunnel. (g) Representative images of CG and
XO staining (n = 4 images per group) for calculating the bone formation rate. OB, old bone; T, bone tunnel. The quantitative analyses of the bone
formation rate at week 3 (h) and week 6 (i) postsurgery were obtained by analyzing the images in part g. The data were analyzed with one-way ANOVA
with Tukey’s post hoc test (n = 4). ***P < 0.001; scale bar, 100 μm (part c).
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“500Dex+icaritin (M)”). The upregulation of another osteo-
genic marker gene Runx2 is insignificant. We speculated that it
was because the Runx2 gene expression data were collected at
late time points, day 7 and 14, while the Runx2 is typically
upregulated in MSCs at early time points upon osteogenic
induction, and correlation between osteogenesis of MSCs and
Runx2 expression becomes less significant at late time points.75
Furthermore, the Ci-I gelatin hydrogels that were loaded with a
bolus dose of icaritin (“500Dex+icaritin (H)”) without icaritin
supplementation produced similar expression levels of the
differentiation marker genes as those of “500Dex+icaritin (M)”,
which received fresh icaritin supplementation after each media
change (Figure 3b). Von Kossa staining (Figure 3c) and the
Runx2, OCN, CEBPα, and PPARγ immunohistochemical
staining (Figure 3d) showed trends consistent with that of the
RT-PCR. These results demonstrate that the Ci-I gelatin
hydrogels are likely capable of mediating sustained delivery of
small hydrophobic molecular drugs (e.g., icaritin) to counteract
the adverse effects (e.g., bone necrosis) of high-concentration
corticosteroids in the long term.
Codelivery of MSC and Icaritin via Ci-I Hydrogels
Enhances Bone Regeneration in SAONModel.We further
evaluated the efficacy of Ci-I gelatin hydrogels encapsulated with
MSCs and icaritin to boost bone regeneration in a SAONmodel.
Figure 4a showed that the injection of Ci-I gelatin hydrogels
helped to prevent a decrease in BMD around the tunnel
compared to the nontreated control group (no hydrogel
implantation, “Blank”). The “icaritin+MSC+Gel” group showed
significantly enhanced new bone formation in the tunnel (Figure
4a). Quantitative measurement of the micro-CT images showed
that the “icaritin+MSC+Gel” group exhibited significant
elevation in BV/TV, trabecular number, while trabecular
thickness and a reduction in trabecular separation, as compared
to the other groups, in both the peri-tunnel native bone (Figure
4b) and neobone tissue inside the tunnel (Figure 4c). Using
Goldener’s Trichrome staining, we also further confirmed that
the bone tunnel was filled with neobone in the “icaritin+MSC
+Gel” group (Figure 4d). In contrast, only fibrous tissue was
formed in the other groups without supplementation of icaritin
(Figure 4d).
We further examined the harvested samples to assess the bone
regeneration within the drilled tunnel. Immunofluorescent
staining against Ki67, a marker widely used to identify
proliferating cells, showed significantly more Ki67 positive
cells in the tunnel region injected with the Ci-I gelatin hydrogels,
which were loaded with both MSCs and icaritin (“icaritin+MSC
+Gel”), as compared to that of either hydrogel alone (“Gel”) or
hydrogel plus icaritin (“icaritin+Gel”) treatment groups (Figure
5a). Moreover, the “icaritin+MSC+Gel” group also exhibited
the most intense staining against key osteogenic markers, Runx2
and Osterix (Figure 5b,c). At week 3 after the hydrogel
implantation, the expressions of active β-catenin and OCN were
upregulated in the “icaritin+MSC+Gel” group (Figure 5d and
Figure S6a) compared to those of the other groups, and this may
have contributed to the enhanced bone formation. In contrast,
PPARγ expression was dramatically decreased (Figure 5e and
Figure S6b), indicating suppressed adipogenesis, and this is
consistent with our previous in vitro findings (Figure 3d). The
icaritin-laden hydrogels (“icaritin+MSC+Gel” and “icaritin
+Gel”) also exhibited significantly elevated expression of
another proliferation marker, proliferating cell nuclear antigen
(PCNA), in addition to Ki67 at week 6 (Figure 5a and Figure
S4), regardless of MSC supplementation. In addition, the
“icaritin+MSC+Gel” group showed slightly reduced expression
of c-Src, a detrimental factor that has been identified as a
therapeutic target for osteonecrosis.55 CSF-1R, a tyrosine-kinase
transmembrane receptor,76 was greatly reduced in the “icaritin
+MSC+Gel” and “icaritin+Gel” groups, indicating the potential
immunoregulative effect of icaritin, as reported by a previous
study.77 More importantly, this finding suggests that icaritin and
Figure 6. (a) Prussian blue and nuclear fast red staining of the histological sections of the femoral heads treated with MSCs and icaritin-laden Ci-I
hydrogels. SPIO positive cells are indicated by green arrows. SPIO positive cells within the tunnel (b) and around the tunnel (c) were counted. The
data were analyzed with one-way ANOVA with Tukey’s post hoc test (n = 6, ***P < 0.001).
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MSCs delivered by Ci-I hydrogels can potentially mitigate the
foreign body response to biomaterial implantations, thereby
facilitating further translational applications.76 By using calcein
green (CG) and xylenol orange (XO) to dynamically assess the
bone formation rate, at week 3 and 6 postsurgery we found that
treatment with hydrogel alone (“Gel”) did not affect bone
formation within the bone tunnel (Figure 5f−i). Incorporation
of icaritin in the injected hydrogels (“icaritin+Gel”) significantly
increased the bone formation rate compared to either blank
repair or the “Gel” group (Figure 5f−i). The encapsulation of
both exogenous MSCs and icaritin in the hydrogels (“icaritin
+MSC+Gel”) further enhanced bone formation in the defect
site (Figure 5f−i). These data demonstrate that the Ci-I gelatin
hydrogel is an excellent carrier of cells and hydrophobic drugs
for promoting in situ bone regeneration and treating SAON.
Delivery of Icaritin by Ci-I Hydrogels Facilitates the
Recruitment of Endogenous Cells To Expedite the
Healing of SAON in Vivo.Our in vitro data have demonstrated
that icaritin-laden Ci-I gelatin hydrogels can attract MSCs to
infiltrate and migrate into hydrogels (Figure 2b). To evaluate
the cell recruitment in vivo, immediately after the core
decompression surgery and treatment with hydrogel injections
in the created tunnel, we injected SPIO-labeledMSCs (1million
cells in 100 μL of media) in the ipsilateral tibia of the same limb.
Six weeks postsurgery, the SPIO-labeled MSCs were hardly
found within and around the tunnels with no hydrogel
implantation (“Blank”) or with blank hydrogel implantation
(“Gel”) (Figure 6). However, significantly more SPIO-labeled
MSCs were found within and around the tunnels which were
injected with hydrogels containing either icaritin alone (“icaritin
+Gel”) or both MSCs and icaritin (“icaritin+MSC+Gel”)
(Figure 6). This is consistent with our previous finding that
icaritin can directly promote the migration of MSCs by
upregulating the expression of vascular cell adhesion molecule-
1 (VCAM-1).54 These data further demonstrated that the
icaritin-laden Ci-I gelatin hydrogels can recruit endogenous
MSCs from the surrounding tissues to migrate to the bone
defects, thereby promoting new bone formation.
■ CONCLUSIONS
Collectively, we demonstrate a unique injectable hydrogel with
desirable properties including ease of preparation, unscathed
mechanical properties after injection, sustained delivery of small
hydrophobic molecular drugs, and injection with encapsulated
cells. Furthermore, the dynamic physical cross-links in this
hydrogel enable the infiltration and migration of cells from the
surrounding environment to speed up the in situ bone
regeneration in a SAON animal model. This injectable hydrogel
can be easily customized to carry different portfolios of
therapeutic drugs and cells for treating a wide array of clinical
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